Shares of the telehealth provider Hims & Hers Health have experienced a dramatic rally following a major strategic reversal and the resolution of a legal dispute. The company is shifting its approach in the lucrative weight-loss medication market by entering an official partnership with pharmaceutical giant Novo Nordisk, a move that has been enthusiastically received by investors.
Market Reaction and Trading Volatility
The announcement triggered significant volatility and buying interest. On Monday, the stock price skyrocketed approximately 41% on exceptionally high trading volume. After that rapid ascent, the share price faced a nearly 8% decline on Thursday as some investors opted to secure profits. However, the upward momentum resumed forcefully on Friday, with shares climbing close to 15%. Cumulatively, this resulted in a weekly gain of roughly 50% for the equity.
This market activity reflects investor analysis of the strategic shift’s implications. The core change involves Hims & Hers discontinuing the sale of compounded, copycat weight-loss drugs. Instead, its platform will now distribute FDA-approved brand-name medications, specifically Novo Nordisk’s Ozempic and Wegovy. Market observers are closely evaluating how the transition from lower-cost alternatives to premium-priced originals will impact future growth rates.
Resolution of Legal Overhang and Analyst Upgrades
The new partnership agreement directly resolves ongoing litigation. Novo Nordisk has agreed to withdraw its patent infringement lawsuit against Hims & Hers, which was initially filed after a prior collaboration failed. The lawsuit alleged the telehealth firm was unlawfully selling copies of Novo’s blockbuster drugs.
Should investors sell immediately? Or is it worth buying Hims & Hers?
The elimination of this legal and regulatory risk prompted several Wall Street firms to swiftly reassess their ratings and price targets for Hims & Hers:
- Barclays raised its price target to $29 from $25, maintaining an “Overweight” rating.
- Bank of America upgraded the stock from “Underperform” to “Neutral” and nearly doubled its target price, moving it to $23 from $12.50.
- Needham & Company upgraded its rating from “Hold” to “Buy,” assigning a new $30 price target.
Strong Quarterly Results and Future Integration Challenge
The positive legal and strategic news was complemented by robust quarterly earnings. Hims & Hers reported a profit of $0.08 per share, surpassing analyst estimates by $0.06. Revenue saw substantial year-over-year growth of 28.4%, reaching nearly $618 million. Furthermore, the company’s subscriber base expanded by 13% to over 2.5 million users.
Looking ahead, the company faces a key operational test: successfully migrating its existing customer base from compounded products to the newly available, higher-priced brand-name medications. The effectiveness of this integration will be a central determinant of the company’s future margin profile. Hims & Hers is expected to provide concrete financial data on the impact of this strategic pivot when it releases its next quarterly results on May 11, 2026.
Ad
Hims & Hers Stock: Buy or Sell?! New Hims & Hers Analysis from March 13 delivers the answer:
The latest Hims & Hers figures speak for themselves: Urgent action needed for Hims & Hers investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 13.
Hims & Hers: Buy or sell? Read more here...
